# Ulcerative Colitis

This is a subcategory of Gastrointestinal Agents.

## Formulary

### Preferred

| Preferred            | Generic Name | Quantity | Time (Days) |
| :------------------- | :----------- | :------: | :---------: |
| Balsalazide Disodium |              |          |             |
| Budesonide ER Tab <sup>QL<sup> |              |          |             |
| Mesalamine DR Cap, Tab   |              |          |             |
| Mesalamine Enema     |              |          |             |
| Mesalamine ER        |              |          |             |
| Pentasa <sup>BvG<sup>          |              |          |             |
| Sulfasalazine        |              |          |             |

### Non-Preferred

| Non-Preferred     | Generic Name | Quantity | Time (Days) |
| :---------------- | :----------- | :------: | :---------: |
| Dipentum          |              |          |             |
| Mesalamine Supp   |              |          |             |
| Uceris Foam <sup>QL<sup>      |              |          |             |
| Zeposia           |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - Budesonide ER 9 MG tablets: 56 tablets per 90 days

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=68)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=24)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
